Promising combo targets Hard-to-Treat sarcomas and lung cancer

NCT ID NCT03449901

Completed Disease control Sponsor: Washington University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jan 04, 2026 · Last updated May 13, 2026 · Updated 19 times

Summary

This study tested a drug called ADI-PEG 20 combined with two chemotherapy drugs (gemcitabine and docetaxel) in 98 people with advanced soft tissue sarcoma, osteosarcoma, Ewing's sarcoma, or small cell lung cancer. The goal was to see if adding ADI-PEG 20, which starves cancer cells of an amino acid, could make the chemotherapy work better. The trial focused on slowing cancer growth and improving survival.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOFT TISSUE SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Columbia University Medical Center

New York, New York, 10032, United States
Sarcoma Oncology Center

Santa Monica, California, 90403, United States
Stanford Medicine

Palo Alto, California, 94304, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.

SOFT TISSUE SARCOMA